Table 1 Characteristics of study completers vs non-completers
From: Clinical trials from the patient perspective: survey in an online patient community
Total (N = 6,815) | Completers (N = 1,621) | Non-completers (N = 5,194) | Test Statistic | p-value | |
|---|---|---|---|---|---|
N | 6,815 | 1,621 | 5,194 | ||
Age (years) a | 7.7 | <0.0001 | |||
Mean ± SD | 53 ± 13 | 55 ± 11 | 52 ± 13 | ||
Unknown, N (%) | 231 (3%) | 0 (0%) | 231 (4%) | ||
Sex, N (%)a | 0.0 | 0.989 | |||
Female | 4,390 (65%) | 1,078 (67%) | 3,312 (64%) | ||
Male | 2,210 (32%) | 543 (33%) | 1,667 (32%) | ||
Unknown | 215 (3%) | 0 (0%) | 215 (4%) | ||
Primary Condition, N (%) | 283.1 | <0.0001 | |||
ALS | 833 (12%) | 160 (10%) | 673 (13%) | ||
T2DM | 1,249 (18%) | 158 (10%) | 1091 (21%) | ||
Epilepsy | 556 (8%) | 131 (8%) | 425 (8%) | ||
Fibromyalgia | 665 (10%) | 241 (15%) | 424 (8%) | ||
MS | 1,000 (15%) | 343 (21%) | 657 (13%) | ||
MDD | 543 (8%) | 91 (5%) | 452 (9%) | ||
PD | 998 (15%) | 319 (20%) | 679 (13%) | ||
RA | 624 (9%) | 125 (8%) | 499 (10%) | ||
SLE | 346 (5%) | 53 (3%) | 293 (5%) |